NASDAQ:BEAM Beam Therapeutics Q3 2025 Earnings Results & Report $23.65 -0.78 (-3.19%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$23.48 -0.17 (-0.72%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Beam Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 4, 2025. The company reported EPS of -$1.10 versus the -$0.98 consensus estimate, while revenue of $9.70 million fell short of the $12.83 million estimate by $3.13 million. Revenue decreased 32.2% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 4, 2025TimeBefore Market OpensConference Call4:00 PM ET Beam Therapeutics EPS ResultsActual EPS-$1.10Consensus EPS -$0.98Beat/MissMissed by -$0.12One Year Ago EPS-$1.17EPS Beat Rate4 of last 8 quartersBeam Therapeutics Revenue ResultsActual Revenue$9.70 millionExpected Revenue$12.83 millionBeat/MissMissed by -$3.13 millionYoY Revenue Growth-32.20%Upcoming EarningsBeam Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Beam Therapeutics Q3 2025 Earnings FAQ Did Beam Therapeutics beat earnings estimates for Q3 2025? Beam Therapeutics (NASDAQ:BEAM) reported earnings of -$1.10 per share for Q3 2025, missing the consensus estimate of -$0.98. The report was announced on Tuesday, November 4, 2025. What was Beam Therapeutics' revenue for Q3 2025? Beam Therapeutics reported revenue of $9.70 million for Q3 2025, against a consensus estimate of $12.83 million. When is Beam Therapeutics' next earnings date? Beam Therapeutics' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Beam Therapeutics on the company's earnings history page. Beam Therapeutics Earnings HeadlinesMixed beam measurement method could help make ion cancer therapy more preciseOctober 14 at 11:41 PM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 13 at 6:03 PM | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressOctober 13 at 8:04 AM | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 8, 2026 | prnewswire.comWells Fargo Sticks to Its Buy Rating for Beam Therapeutics (BEAM)October 7, 2026 | theglobeandmail.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments. Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders. Its pipeline has included investigational programs such as BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia. These programs are investigational and remain subject to clinical and regulatory evaluation. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was established by scientists and entrepreneurs including David Liu, a pioneer in base-editing technology. John Evans has served as the company’s chief executive officer. Beam’s operations are centered on advancing its proprietary editing platform and developing genetic medicines for patients with serious diseases.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
